Company

Lyric Biosciences Inc.

Lyric Biosciences develops human immunoglobulin products using bioreactor technology.

About

Founded in 2024 in San Francisco, Lyric Biosciences develops human immunoglobulin products using bioreactor technology and a laser-printed cellular substrate. Its approach is intended to enable continuous production and reduce reliance on blood and plasma donations. The company plans to expand its biomanufacturing platform, initially focusing on IVIg production. In December 2025, it raised USD 6.6 million in Seed funding led by The Venture Collective, with SOSV and other investors participating.

2Funding rounds

4Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in